Pharmacological inhibitors targeting ADAM-family members suppress acute and asthmatic inflammatory responses and S. aureus virulence, highlighting their potential as therapeutic targets.
ADAM-family metalloproteinases play crucial roles in lung inflammation and represent potential therapeutic targets, though their roles in tissue repair must be considered to avoid side effects.
Acute and chronic lung inflammation is driven and controlled by several endogenous mediators that undergo proteolytic conversion from surface-expressed proteins to soluble variants by a disintegrin and metalloproteinase (ADAM)-family members. TNF and epidermal growth factor receptor ligands are just some of the many substrates by which these proteases regulate inflammatory or regenerative processes in the lung. ADAM10 and ADAM17 are the most prominent members of this protease family. They are constitutively expressed in most lung cells and, as recent research has shown, are the pivotal shedding enzymes mediating acute lung inflammation in a cell-specific manner. ADAM17 promotes endothelial and epithelial permeability, transendothelial leukocyte migration, and inflammatory mediator production by smooth muscle and epithelial cells. ADAM10 is critical for leukocyte migration and alveolar leukocyte recruitment. ADAM10 also promotes allergic asthma by driving B cell responses. Additionally, ADAM10 acts as a receptor for Staphylococcus aureus (S. aureus) α-toxin and is crucial for bacterial virulence. ADAM8, ADAM9, ADAM15, and ADAM33 are upregulated during acute or chronic lung inflammation, and recent functional or genetic analyses have linked them to disease development. Pharmacological inhibitors that allow us to locally or systemically target and differentiate ADAM-family members in the lung suppress acute and asthmatic inflammatory responses and S. aureus virulence. These promising results encourage further research to develop therapeutic strategies based on selected ADAMs. These studies need also to address the role of the ADAMs in repair and regeneration in the lung to identify further therapeutic opportunities and possible side effects.
Dreymueller et al. (Sat,) conducted a review in Acute and chronic lung inflammation. Pharmacological inhibitors of ADAM-family members was evaluated. Pharmacological inhibitors targeting ADAM-family members suppress acute and asthmatic inflammatory responses and S. aureus virulence, highlighting their potential as therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: